SCHEMBL1749302

SCHEMBL1749302

CCOC(=O)c1nc(Cl)nc(NC2CCC(NC(=O)OC(C)(C)C)CC2)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 5/20 0.41
MERTK Q12866 1/20 0.40
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DRD2 P14416 3/20 0.35
DRD3 P35462 2/20 0.35
CHRM4 P08173 1/20 0.35
KDM1A O60341 1/20 0.34
MAOB P27338 1/20 0.34
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749305 1.00 BTK (0.41) BTKMERTKKDM4ENPC1ALDH1A1
SCHEMBL1750136 0.85 IGF1R (0.40) BTKMERTKDRD2DRD3KDM1A
SCHEMBL1750135 0.85 IGF1R (0.40) BTKMERTKDRD2DRD3KDM1A
SCHEMBL4226011 0.84 NOS2 (0.46) BTKKDM4ENPC1ALDH1A1MAPT
SCHEMBL16202703 0.80 MERTK (0.49) BTKMERTKKDM4ENPC1ALDH1A1
SCHEMBL1749640 0.80 BTK (0.41) BTKMERTKKDM1AMAOBCKS1B
SCHEMBL1749641 0.80 BTK (0.41) BTKMERTKKDM1AMAOBCKS1B
SCHEMBL1749360 0.74 MAPK8 (0.43) CYP2C9NPR3CYP2C19
SCHEMBL1749359 0.74 MAPK8 (0.43) CYP2C9NPR3CYP2C19
SCHEMBL1938108 0.74 BTK (0.44) BTKMERTKDRD2DRD3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383634-B2 Methods of treatment using heteroaryl compounds and compositions thereof SIGNAL PHARMACEUTICALS, LLC (US) 2013-02-26 US disclosed
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF SIGNAL PHARMACEUTICALS, LLC 2011-09-15 US disclosed
US-7968556-B2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2011-06-28 US disclosed
EP-2078018-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2009-07-15 EP disclosed
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2009-02-12 US disclosed
WO-2008051494-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF JAK2, CHEK2, PHKG1 BTK 22/4885MERTK 401/4885KDM4E 1690/4885
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith JAK2, CHEK2, SRC BTK 49/4885MERTK 535/4885KDM4E 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.